Table 3.

Logistic derived odds ratio (OR) together with 95% confidence interval (95% CI) for systemic adverse reactions (SARs) following the first and second dose of the BNT162b2 vaccine by the study variables. Cumulative score includes fatigue, headache, myalgias-arthralgias, fever, gastrointestinal symptoms, lymphadenopathy and chills

Variable	Vaccine dose	Fatigue	Headache	Myalgias-Arthralgias	Fever	GI symptoms	LA	Chills	Cumulative score of SARs
Gender (female vs male)	1st	2.61	2.57	2.37	0.72	0.75	0.83	-	2.57
		1.14–5.95	1.13–5.86	0.90–6.25	0.05–9.69	0.07–7.83	0.06–12.15	-	1.39–4.73
	2nd	2.06	2.73	3.08	1.78	1.87	1.87	3.59	2.71
		1.26–3.35	1.53–4.86	1.73–5.49	0.83–3.84	0.51–6.90	0.51–6.90	1.06–12.24	1.76–4.19
Age group (10 years more)	1st	0.90	0.87	0.89	0.47	0.81	0.31	-	0.85
		0.72–1.12	0.69–1.09	0.68–1.16	0.15–1.48	0.35–1.87	0.08–1.25	-	0.71–1.01
	2nd	0.74	0.78	0.70	0.65	0.62	0.58	0.57	0.66
		0.63–0.87	0.66–0.93	0.59–0.83	0.51–0.82	0.38–1.00	0.38–0.89	0.42–0.76	0.57–0.76
BMI (1 category more)	1st	0.83	0.89	1.06	0.80	0.45	0.92	-	0.95
		0.55–1.24	0.61–1.31	0.68–1.66	0.09–6.80	0.06–3.56	0.11–7.96	-	0.70–1.29
	2nd	0.84	1.05	0.97	0.69	0.74	1.42	0.90	0.97
		0.64–1.11	0.78–1.41	0.73–1.30	0.44–1.07	0.29–1.88	0.71–2.85	0.53–1.52	0.76–1.23
Underlying disease (Yes vs No)	1st	0.92	1.55	1.05	-	0.48	-	-	1.08
		0.54–1.58	0.91–2.67	0.56–2.00	-	0.05–4.90	-	-	0.70–1.65
	2nd	0.97	0.88	1.09	1.41	1.81	0.83	2.13	1.05
		0.66–1.43	0.58–1.34	0.72–1.64	0.81–2.48	0.57–5.75	0.30–2.31	1.04–4.37	0.75–1.48
Smoking (Yes vs No)	1st	0.87	1.01	1.49	1.81	0.96	2.06	-	1.12
		0.48–1.57	0.56–1.79	0.78–2.85	0.15–21.29	0.10–9.47	0.17–25.22	-	0.71–1.77
	2nd	0.72	0.83	1.14	1.03	0.87	0.57	1.37	0.81
		0.47–1.09	0.53–1.32	0.74–1.77	0.56–1.90	0.23–3.25	0.16–2.04	0.65–2.89	0.56–1.17

Abbreviations: BMI: body mass index; GI: gastrointestinal; LA: lymphadenopathy

Statistically significant (p-value < 0.05) results are marked in bold.